AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06148376 — intervention group
Intervention type: OTHER
Intervention: Personalized treatment
Description: Discontinue prandial insulin treatment
Study NCT05502575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring and personalized stress management
Description: Self-monitoring and personalized stress management education and materials.
Study NCT05502575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring and general stress management
Description: Self-monitoring and general stress management education and materials.
Study NCT06394011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax, azacitidine and HAAG regimen
Description: Venetoclax:100mg, qd, d1;200mg, qd, d2;400 mg, qd, d3\~10, per os; Azacitidine:75mg/m2/d, d1\~7, subcutaneous injection; Homoharringtonine:1mg/d, d4\~10, intravenous infusion; Aclarubicin:10mg/d, d4\~7, intravenous infusion; Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
Study NCT03141736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KMC & WHO protocol (0-1 hour)
Description: WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
Study NCT03141736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KMC, WHO protocol & bag (0-1 hour)
Description: In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
Study NCT03141736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KMC & WHO protocol (1-24 hours)
Description: WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
Study NCT03141736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KMC, WHO protocol & bag (1-24 hours)
Description: In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
Study NCT05654389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital
Description: Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
Study NCT06279767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: 6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.
Study NCT05464888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: +Short AAT
Description: Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
Study NCT05464888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: +Long AAT
Description: Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
Study NCT05464888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control; NO dog
Description: Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
Study NCT04677959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FS)
Description: FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
Study NCT04677959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
Study NCT04677959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Asthma Medication
Description: Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
Study NCT04677959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rescue Medication
Description: Current rescue medication
Study NCT04921735 — intervention group
Intervention type: DRUG
Intervention: Cisatracurium
Description: 0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
Study NCT05076383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group (Motor relearning program)
Description: Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
Study NCT05076383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Conventional physical therapy program)
Description: The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
Study NCT05329376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Speaker Echo Dot
Description: Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:~1. Medication reminders~2. Glucose test reminders:~3. Educational health tips~4. Weekly educational podcasts~5. Good morning and good night routine
Study NCT05329376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment
Study NCT03957265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tapered abutment connection
Description: Rehabilitation of completely edentulous patients with overdentures prostheses.
Study NCT05468554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
Study NCT06300112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YOGA
Description: Yoga will be applied to the experimental group for a total of 12 sessions, two sessions per week (90 minutes) for six weeks.
Study NCT04941209 — intervention group
Intervention type: DEVICE
Intervention: imPulse™ Una infrasound-to-ultrasound e-stethoscope
Description: The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
Study NCT04941209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: (PPA >95%) FDA EUA RT-PCR
Description: Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.
Study NCT04941209 — intervention group
Intervention type: RADIATION
Intervention: HR-CT-scan
Description: High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
Study NCT05060367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal multivitamin/mineral
Description: Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
Study NCT05060367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard multivitamin/mineral
Description: Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
Study NCT04911452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calmer
Description: Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
Study NCT06267755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave therapy
Description: the patients will receive Extracorporeal Shockwave therapy sessions by 600 impulses with 1.6 bar pressure at a frequency of 8 Hz on site of the upper trapezius
Study NCT06267755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
Study NCT06267755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
Study NCT05738642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 factor Prothrombin Complex Concentrates
Description: Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
Study NCT05468554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioactive iodine (I-131)
Description: Patients qualified to receive 131I treatment
Study NCT05468554 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radioactive iodine (I-131)
Description: Patients qualified to receive 131I treatment
Study NCT05293834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Aggression Prevention Training (VRAPT)
Description: VRAPT consists of sixteen 45- to 60-minute sessions that take place once or twice per week (total duration of the intervention = 8 to 16 weeks). Session time and intensity will be adapted to the individual participant and the sessions will be delivered by specially trained VRAPT therapists in individual settings. The immersive and interactive three-dimensional virtual environment will be presented via headphones and head-mounted displays, using software developed by CleVR. In the virtual environment, participants will interact with virtual characters that are controlled by the psychotherapist and practice new skills . The therapy program is targeted at factors and processes related to aggression and the underlying theoretical framework is based on cognitive behavioural therapy and the General Aggression Model (GAM).~The VRAPT consists of 4 phases:~1. Introduction (Session 1)~2. Inventory phase (Sessions 2-6)~3. Skills-training (Sessions 6-15)~4. Evaluation (Session 16)
Study NCT05709964 — intervention group
Intervention type: OTHER
Intervention: Self-reported
Description: Self-reported height, weight, and neck circumference
Study NCT05709964 — intervention group
Intervention type: OTHER
Intervention: Measured
Description: Height, weight, and neck circumference measured by the investigator.
Study NCT06100822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg capsules of Metformin Extended Release
Study NCT06100822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg capsules of placebo pills
Study NCT05482464 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Casein glycomacropeptide (CGMP)
Description: Casein glycomacropeptide (CGMP) supplementation for 3 weeks
Study NCT05106322 — intervention group
Intervention type: OTHER
Intervention: intraoperative spectrometer scan
Description: intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
Study NCT06470256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palliative Hepatectomy
Description: Patients will receive TACE, HAIC, or 90Y-SIRT combined with Lenvatinib and Durvalumab. After receiving three months of combined treatment, patients in the SD or PD stage who have poor efficacy evaluated by imaging will undergo palliative hepatectomy.~Palliative Hepatectomy:① Intrahepatic metastasis: complete lesion resection of the main tumor on one side of the liver; ② Extrahepatic metastasis: complete lesion resection of intrahepatic lesions; ③ Merge portal vein tumor thrombus or hepatic vein tumor thrombus: remove the tumor thrombus and completely remove the intrahepatic lesions. And reduce the tumor burden by more than 90% through surgical resection.
Study NCT06470256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab.
Study NCT06470256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Three weeks post-surgery, patients commenced oral administration of Lenvatinib.
Study NCT04389281 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: X-PACT
Description: X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
Study NCT05281302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck muscle vibration
Description: Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.
Study NCT05281302 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neck muscle vibration + sham-tDCS
Description: Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy.. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. The tDCS will be automatically turned off after 20 seconds. This allows the reproduction of the initial mild itching sensation at the beginning of active tDCS, thus ensuring that the patient stays blind to the activation status of the device.
Study NCT05281302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck muscle vibration + anodal-tDCS
Description: Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. A continuous 2 mA current will be delivered for 20 minutes simultaneously to NMV stimulation. The stimulation will begin 5 minutes before the beginning of occupational therapy.
Study NCT05257850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal therapy
Description: A high-flow nasal therapy for 30 minutes.
Study NCT05257850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airflow directed to face by a fan
Description: A fan directed to the face for 30 minutes
Study NCT05227521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted H-GRASP feedback program
Description: Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
Study NCT05687331 — intervention group
Intervention type: PROCEDURE
Intervention: knee arthrocentesis
Description: arthrocentesis of the knee joint to gather a synovial fluid sample
Study NCT05687331 — intervention group
Intervention type: PROCEDURE
Intervention: venipuncture
Description: Peripheral venipuncture to gather a blood sample
Study NCT05687331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-scan
Description: MRI-scan of the knee
Study NCT05687331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Physical examination of the injured knee
Study NCT05687331 — intervention group
Intervention type: OTHER
Intervention: KOOS questionnaire
Description: KOOS questionnaire of the injured knee
Study NCT04530942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation(Active)
Description: DBS On with the optiomal parameters
Study NCT04530942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation(Sham)
Description: DBS On with 0V Amplitude
Study NCT04479579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 milligram
Description: apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
Study NCT04562207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening for respiratory virus infection
Description: Nasopharyngeal swab for screening for respiratory virus infection before surgery
Study NCT05241990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.
Study NCT05241990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Stepped Care
Description: Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
Study NCT05288790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Dietary supplement
Study NCT05288790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet
Study NCT05030870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Description: Standard monitoring and capnographic monitoring.
Study NCT05030870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard monitoring
Description: Standard monitoring but no capnographic monitoring
Study NCT05030870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring but no capnographic monitoring
Study NCT05703971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quaratusugene ozeplasmid
Description: Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
Study NCT05703971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
Study NCT06082986 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.